Latest QuantiFERON Stories
In populations with a low prevalence of tuberculosis (TB), the majority of positives with the three tests commercially available in the U.S for the diagnosis of TB are false positives, according to a new study.
Cellestis has launched the TB Operation Support Solution (TBoss), a comprehensive service to help support U.S.
Despite being widely available for sale in low-and-middle income countries, commercial serological tests used to detect active tuberculosis (by identifying antibodies to the tuberculosis-causing bacterium in a blood sample) do not accurately diagnose TB and, furthermore, often test positive when the patient does not have TB (false positive) and test negative when the patient actually has TB (false negative).
MELBOURNE, Australia, July 25, 2011 /PRNewswire/ -- A new policy recommendation released on 20 July by the World Health Organization (WHO) warns against the use of serological (blood) tests to diagnose active tuberculosis (TB).
Blood tests commonly used to detect tuberculosis can be unreliable and potentially dangerous to patients, according to a World Health Organization (WHO) warning issued on Sunday.
VENLO, The Netherlands and MELBOURNE, Australia, July 11, 2011 /PRNewswire/ -- - QIAGEN increases offer to shareholders of Cellestis Limited (CST:AU) pursuant to scheme of arrangement - Cellestis board of directors unanimously support amended proposal offering its shareholders a 7% increase to A$3.80 per share from original offer of A$3.55 - Acquisition would provide QIAGEN with exclusive access to...
VENLO, Netherlands and MELBOURNE, Australia, April 3, 2011 /PRNewswire/ -- QIAGEN N.V.
VALENCIA, Calif., June 24 /PRNewswire/ -- Today the United States (U.S.) Centers for Disease Control and Prevention (CDC) issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, the causative agent of tuberculosis (TB).
- Emitting flashes of light; glittering.